C.R. Bartram, A. de Klein, A. Hagemeijer, T. van Agthoven, A.G. van Kessel, D. Bootsma, G. Grosveld, M.A. Ferguson-Smith, T. Davies, M. Stone, Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 306(5940), 277–280 (1983)

Article  CAS  PubMed  Google Scholar 

B.J. Druker, F. Guilhot, S.G. O’Brien, I. Gathmann, H. Kantarjian, N. Gattermann, M.W.N. Deininger, R.T. Silver, J.M. Goldman, R.M. Stone, F. Cervantes, A. Hochhaus, B.L. Powell, J.L. Gabrilove, P. Rousselot, J. Reiffers, J.J. Cornelissen, T. Hughes, H. Agis, T. Fischer, G. Verhoef, J. Shepherd, G. Saglio, A. Gratwohl, J.L. Nielsen, J.P. Radich, B. Simonsson, K. Taylor, M. Baccarani, C. So, L. Letvak, R.A. Larson, IRIS Investigators, Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355(23), 2408–2417 (2006)

Article  Google Scholar 

H. de Lavallade, J.F. Apperley, J.S. Khorashad, D. Milojkovic, A.G. Reid, M. Bua, R. Szydlo, E. Olavarria, J. Kaeda, J.M. Goldman, D. Marin, Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 26(20), 3358–3363 (2008)

Article  Google Scholar 

M. Baccarani, M.W. Deininger, G. Rosti, A. Hochhaus, S. Soverini, J.F. Apperley, F. Cervantes, R.E. Clark, J.E. Cortes, F. Guilhot, H. Hjorth-Hansen, T.P. Hughes, H.M. Kantarjian, D.-W. Kim, R.A. Larson, J.H. Lipton, F.-X. Mahon, G. Martinelli, J. Mayer, M.C. Müller, D. Niederwieser, F. Pane, J.P. Radich, P. Rousselot, G. Saglio, S. Saußele, C. Schiffer, R. Silver, B. Simonsson, J.-L. Steegmann, J.M. Goldman, R. Hehlmann, European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6), 872–884 (2013)

Article  CAS  PubMed  PubMed Central  Google Scholar 

S. Soverini, S. Branford, F.E. Nicolini, M. Talpaz, M.W.N. Deininger, G. Martinelli, M.C. Müller, J.P. Radich, N.P. Shah, Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res. 38(1), 10–20 (2014)

Article  CAS  PubMed  Google Scholar 

T. Schindler, W. Bornmann, P. Pellicena, W.T. Miller, B. Clarkson, J. Kuriyan, Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289(5486), 1938–1942 (2000)

Article  CAS  PubMed  Google Scholar 

B. Nagar, W.G. Bornmann, P. Pellicena, T. Schindler, D.R. Veach, W.T. Miller, B. Clarkson, J. Kuriyan, Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62(15), 4236–4243 (2002)

CAS  PubMed  Google Scholar 

A.S. Corbin, A. Agarwal, M. Loriaux, J. Cortes, M.W. Deininger, B.J. Druker, Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J. Clin. Invest. 121(1), 396–409 (2011)

Article  CAS  PubMed  Google Scholar 

S.M. Graham, H.G. Jørgensen, E. Allan, C. Pearson, M.J. Alcorn, L. Richmond, T.L. Holyoake, Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99(1), 319–325 (2002)

Article  CAS  PubMed  Google Scholar 

X. Jiang, Y. Zhao, C. Smith, M. Gasparetto, A. Turhan, A. Eaves, C. Eaves, Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 21(5), 926–935 (2007)

Article  CAS  PubMed  Google Scholar 

H. Herrmann, I. Sadovnik, S. Cerny-Reiterer, T. Rülicke, G. Stefanzl, M. Willmann, G. Hoermann, M. Bilban, K. Blatt, S. Herndlhofer, M. Mayerhofer, B. Streubel, W.R. Sperr, T.L. Holyoake, C. Mannhalter, P. Valent, Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. Blood 123(25), 3951–3962 (2014)

Article  CAS  PubMed  Google Scholar 

F. Pellicano, M.T. Scott, G.V. Helgason, L.E.M. Hopcroft, E.K. Allan, M. Aspinall-O’Dea, M. Copland, A. Pierce, B.J.P. Huntly, A.D. Whetton, T.L. Holyoake, The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors. Stem. Cells Dayt. Ohio 32(9), 2324–2337 (2014)

Article  CAS  Google Scholar 

C. Hurtz, K. Hatzi, L. Cerchietti, M. Braig, E. Park, Y. Kim, S. Herzog, P. Ramezani-Rad, H. Jumaa, M.C. Müller, W.-K. Hofmann, A. Hochhaus, B.H. Ye, A. Agarwal, B.J. Druker, N.P. Shah, A.M. Melnick, M. Müschen, BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J. Exp. Med. 208(11), 2163–2174 (2011)

Article  CAS  PubMed  PubMed Central  Google Scholar 

L. Jin, Y. Tabe, S. Konoplev, Y. Xu, C.E. Leysath, H. Lu, S. Kimura, A. Ohsaka, M.-B. Rios, L. Calvert, H. Kantarjian, M. Andreeff, M. Konopleva, CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol. Cancer Ther. 7(1), 48–58 (2008)

Article  CAS  PubMed  Google Scholar 

H. Xie, C. Peng, J. Huang, B.E. Li, W. Kim, E.C. Smith, Y. Fujiwara, J. Qi, G. Cheloni, P.P. Das, M. Nguyen, S. Li, J.E. Bradner, S.H. Orkin, Chronic myelogenous leukemia- initiating cells require polycomb group protein EZH2. Cancer Discov. 6(11), 1237–1247 (2016)

Article  CAS  PubMed  PubMed Central  Google Scholar 

M.A. Gonzalez, I.M. Olivas, A.E. Bencomo-Alvarez, A.J. Rubio, C. Barreto-Vargas, J.L. Lopez, S.K. Dang, J.P. Solecki, E. McCall, G. Astudillo, V.V. Velazquez, K. Schenkel, K. Reffell, M. Perkins, N. Nguyen, J.N. Apaflo, E. Alvidrez, J.E. Young, J.J. Lara, D. Yan, A. Senina, J. Ahmann, K.E. Varley, C.C. Mason, C.A. Eide, B.J. Druker, M. Nurunnabi, O. Padilla, S. Bajpeyi, A.M. Eiring, Loss of G0/G1 switch gene 2 (G0S2) promotes disease progression and drug resistance in chronic myeloid leukaemia (CML) by disrupting glycerophospholipid metabolism. Clin. Transl. Med. 12(12), e1146 (2022)

Article  CAS  PubMed  PubMed Central  Google Scholar 

Y. Wang, Y. Liu, S.N. Malek, P. Zheng, Y. Liu, Targeting HIF1α eliminates cancer stem cells in hematological malignancies. Cell. Stem. Cell. 8(4), 399–411 (2011)

Article  CAS  PubMed  PubMed Central  Google Scholar 

Y.-H. Wang, W.J. Israelsen, D. Lee, V.W.C. Yu, N.T. Jeanson, C.B. Clish, L.C. Cantley, M.G. Vander Heiden, D.T. Scadden, Cell-state-specific metabolic dependency in hematopoiesis and leukemogenesis. Cell. 158(6), 1309–1323 (2014)

Article  CAS  PubMed  PubMed Central  Google Scholar 

Y. Saito, R.H. Chapple, A. Lin, A. Kitano, D. Nakada, AMPK protects leukemia-initiating cells in myeloid leukemias from metabolic stress in the bone marrow. Cell. Stem. Cell. 17(5), 585–596 (2015)

Article  CAS  PubMed  PubMed Central  Google Scholar 

L. Liu, R. Chen, S. Huang, Y. Wu, G. Li, Q. Liu, D. Yin, Y. Liang, Knockdown of SOD1 sensitizes the CD34+ CML cells to imatinib therapy. Med. Oncol. Northwood Lond. Engl. 28(3), 835–839 (2011)

Article  CAS  Google Scholar 

Y. Chen, Y. Hu, H. Zhang, C. Peng, S. Li, Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat. Genet. 41(7), 783–792 (2009)

Article  CAS  PubMed  PubMed Central  Google Scholar 

A. Hattori, M. Tsunoda, T. Konuma, M. Kobayashi, T. Nagy, J. Glushka, F. Tayyari, D. McSkimming, N. Kannan, A. Tojo, A.S. Edison, T. Ito, Cancer progression by reprogrammed BCAA metabolism in myeloid leukaemia. Nature 545(7655), 500–504 (2017)

Article  CAS  PubMed  PubMed Central  Google Scholar 

S. Raffel, M. Falcone, N. Kneisel, J. Hansson, W. Wang, C. Lutz, L. Bullinger, G. Poschet, Y. Nonnenmacher, A. Barnert, C. Bahr, P. Zeisberger, A. Przybylla, M. Sohn, M. Tönjes, A. Erez, L. Adler, P. Jensen, C. Scholl, S. Fröhling, S. Cocciardi, P. Wuchter, C. Thiede, A. Flörcken, J. Westermann, G. Ehninger, P. Lichter, K. Hiller, R. Hell, C. Herrmann, A.D. Ho, J. Krijgsveld, B. Radlwimmer, A. Trumpp, BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation. Nature 551(7680), 384–388 (2017)

Article  CAS  PubMed  Google Scholar 

P. Gulati, L.D. Gaspers, S.G. Dann, M. Joaquin, T. Nobukuni, F. Natt, S.C. Kozma, A.P. Thomas, G. Thomas, Amino acids activate mTOR complex 1 via Ca2+/CaM signaling to hVps34. Cell. Metab. 7(5), 456–465 (2008)

Article  CAS  PubMed  PubMed Central  Google Scholar 

F. Mercan, H. Lee, S. Kolli, A.M. Bennett, Novel role for SHP-2 in nutrient-responsive control of S6 kinase 1 signaling. Mol. Cell. Biol. 33(2), 293–306 (2013)

Article  CAS  PubMed  PubMed Central  Google Scholar 

K. Sato, A. Suematsu, T. Nakashima, S. Takemoto-Kimura, K. Aoki, Y. Morishita, H. Asahara, K. Ohya, A. Yamaguchi, T. Takai, T. Kodama, T.A. Chatila, H. Bito, H. Takayanagi, Regulation of osteoclast differentiation and function by the CaMK-CREB pathway. Nat. Med. 12(12), 1410–1416 (2006)

Article  CAS  PubMed